HKG:2607 Revenue

Shanghai Pharmaceuticals Holding had revenue of 73.48B CNY in the quarter ending September 30, 2025, with 4.65% growth. This brings the company's revenue in the last twelve months to 280.69B, up 3.04% year-over-year. In the year 2024, Shanghai Pharmaceuticals Holding had annual revenue of 275.25B with 5.75% growth.

Revenue (ttm)

280.69B CNY

Revenue Growth

+3.04%

P/S Ratio

0.21

Revenue / Employee

5.68M CNY

Employees

49,402

Market Cap

65.42B HKD

Revenue Chart

* This company reports financials in CNY.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	275.25B	14.96B	5.75%
Dec 31, 2023	260.30B	28.31B	12.21%
Dec 31, 2022	231.98B	16.16B	7.49%
Dec 31, 2021	215.82B	23.92B	12.46%
Dec 31, 2020	191.91B	5.34B	2.86%
Dec 31, 2019	Upgrade Pro	Upgrade Pro	Upgrade Pro
Dec 31, 2018	Upgrade Pro	Upgrade Pro	Upgrade Pro
Dec 31, 2017	Upgrade Pro	Upgrade Pro	Upgrade Pro
Dec 31, 2016	Upgrade Pro	Upgrade Pro	Upgrade Pro
Dec 31, 2015	Upgrade Pro	Upgrade Pro	Upgrade Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
JD Health International	71.34B
BeOne Medicines AG	35.81B
Sino Biopharmaceutical	33.49B
Alibaba Health Information Technology	32.81B
CSPC Pharmaceutical Group	28.49B
WuXi Biologics	21.98B
Hansoh Pharmaceutical Group Company	14.45B
Innovent Biologics	12.52B

Revenue Rankings

Shanghai Pharmaceuticals Holding News

10 months ago - Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million - Benzinga
10 months ago - HUTCHMED to divest 45% stake in JV with Shanghai Pharma - Seeking Alpha

More News